Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 368681, 11 pages
http://dx.doi.org/10.1155/2014/368681
Research Article

Prediction of Methotrexate Clinical Response in Portuguese Rheumatoid Arthritis Patients: Implication of MTHFR rs1801133 and ATIC rs4673993 Polymorphisms

1CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Pharmaceutical Sciences, Higher Institute of Health Sciences (ISCS-N), Rua Central de Gandra 1317, 4585-116 Gandra PRD, Portugal
2Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal
3Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
4Faculty of Medicine of University of Porto (FMUP), Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
5Rheumatology Department, São João Hospital Center, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
6Virology Service, Portuguese Institute of Oncology of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal
7Research Department-Portuguese League Against Cancer (LPCC-NRNorte), Estrada Interior da Circunvalação 6657, 4200-177 Porto, Portugal

Received 28 February 2014; Revised 22 April 2014; Accepted 22 April 2014; Published 21 May 2014

Academic Editor: Miguel A. González-Gay

Copyright © 2014 Aurea Lima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. B. Imboden, D. B. Hellmann, and J. H. Stone, “Rheumatoid arthritis: the disease-diagnosis and clinical features,” in Current Rheumatology Diagnosis & Treatment, J. B. Imboden, D. B. Hellmann, and J. H. Stone, Eds., p. 508, McGraw Hill Professional, 2nd edition, 2006. View at Google Scholar
  2. J. W. van der Heijden, B. A. C. Dijkmans, R. J. Scheper, and G. Jansen, “Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside,” Nature Clinical Practice Rheumatology, vol. 3, no. 1, pp. 26–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Anderson, G. Wells, A. C. Verhoeven, and D. T. Felson, “Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration,” Arthritis & Rheumatism, vol. 43, no. 1, pp. 22–29, 2000. View at Google Scholar
  4. J. E. Fonseca, H. Canhão, J. C. Teixeira da Costa, J. A. Pereira da Silva, and M. Viana Queiroz, “Global functional status in rheumatoid arthritis: disease duration and patient age,” Clinical Rheumatology, vol. 21, no. 1, pp. 32–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Rönnelid, M. C. Wick, J. Lampa et al., “Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression,” Annals of the Rheumatic Diseases, vol. 64, no. 12, pp. 1744–1749, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. N. G. Papadopoulos, Y. Alamanos, P. V. Voulgari, E. K. Epagelis, N. Tsifetaki, and A. A. Drosos, “Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?” Clinical and Experimental Rheumatology, vol. 23, no. 6, pp. 861–866, 2005. View at Google Scholar · View at Scopus
  7. J. Morel and B. Combe, “How to predict prognosis in early rheumatoid arthritis,” Best Practice and Research: Clinical Rheumatology, vol. 19, no. 1, pp. 137–146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. L. Hider, C. Buckley, A. J. Silman, D. P. M. Symmons, and I. N. Bruce, “Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 32, no. 1, pp. 11–16, 2005. View at Google Scholar · View at Scopus
  9. A. H. M. van der Helm-van Mil, K. N. Verpoort, F. C. Breedveld, R. E. M. Toes, and T. W. J. Huizinga, “Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis,” Arthritis Research & Therapy, vol. 7, no. 5, pp. R949–R958, 2005. View at Google Scholar · View at Scopus
  10. W. Urano, A. Taniguchi, H. Yamanaka et al., “Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses,” Pharmacogenetics, vol. 12, no. 3, pp. 183–190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Aggarwal, S. Naik, K. P. Mishra, A. Aggarwal, and R. Misra, “Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation,” Indian Journal of Medical Research, vol. 124, pp. 521–526, 2006. View at Google Scholar · View at Scopus
  12. P. Ranganathan and H. L. McLeod, “Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 5, pp. 1366–1377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. M. Wessels, J. K. de Vries-Bouwstra, B. T. Heijmans et al., “Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes,” Arthritis & Rheumatism, vol. 54, no. 4, pp. 1087–1095, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. C. K. Iannaccone, Y. C. Lee, J. Cui et al., “Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study,” Rheumatology, vol. 50, no. 1, pp. 40–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Owen, S. L. Hider, P. Martin, I. N. Bruce, A. Barton, and W. Thomson, “Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients,” Pharmacogenomics Journal, vol. 13, no. 3, pp. 227–234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Dervieux, D. Furst, D. O. Lein et al., “Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 50, no. 9, pp. 2766–2774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. K. I. Halilova, E. E. Brown, S. L. Morgan et al., “Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?” International Journal of Rheumatology, vol. 2012, Article ID 978396, 7 pages, 2012. View at Publisher · View at Google Scholar
  18. V. C. Romao, H. Canhao, and J. E. Fonseca, “Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?” BMC Medicine, vol. 11, article 17, 2013. View at Google Scholar
  19. E. S. Vesell, “Advances in pharmacogenetics and pharmacogenomics,” Journal of Clinical Pharmacology, vol. 40, no. 9, pp. 930–938, 2000. View at Google Scholar · View at Scopus
  20. H. Tian and B. N. Cronstein, “Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis,” Bulletin of the NYU Hospital for Joint Diseases, vol. 65, no. 3, pp. 168–173, 2007. View at Google Scholar · View at Scopus
  21. E. S. L. Chan and B. N. Cronstein, “Molecular action of methotrexate in inflammatory diseases,” Arthritis Research, vol. 4, no. 4, pp. 266–273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. A. E. van Ede, R. F. Laan, H. J. Blom, R. A. De Abreu, and L. B. A. Van de Putte, “Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity,” Seminars in Arthritis and Rheumatism, vol. 27, no. 5, pp. 277–292, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Palmer and R. H. Abeles, “The mechanism of action of S-adenosylhomocysteinase,” Journal of Biological Chemistry, vol. 254, no. 4, pp. 1217–1226, 1979. View at Google Scholar · View at Scopus
  24. T. Dervieux, N. Greenstein, and J. Kremer, “Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 10, pp. 3095–3103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Kurzawski, A. Pawlik, K. Safranow, M. Herczynska, and M. Drozdzik, “677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis,” Pharmacogenomics, vol. 8, no. 11, pp. 1551–1559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. C. Lee, J. Cui, K. H. Costenbader, N. A. Shadick, M. E. Weinblatt, and E. W. Karlson, “Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate,” Rheumatology, vol. 48, no. 6, pp. 613–617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Hinks, H. Moncrieffe, P. Martin et al., “Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 8, pp. 1395–1400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Owen, M. Lunt, J. Bowes et al., “MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms,” Pharmacogenomics Journal, vol. 13, no. 2, pp. 137–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Frosst, H. J. Blom, R. Milos et al., “A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase,” Nature Genetics, vol. 10, no. 1, pp. 111–113, 1995. View at Google Scholar · View at Scopus
  30. D. Aletaha, T. Neogi, and A. J. Silman, “2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1580–1588, 2010. View at Google Scholar
  31. Z. Ortiz, B. Shea, M. Suarez Almazor, D. Moher, G. Wells, and P. Tugwell, “Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD000951, 2000. View at Google Scholar · View at Scopus
  32. Z. Ortiz, B. Shea, M. E. Suarez-Almazor, D. Moher, G. A. Wells, and P. Tugwell, “The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials,” Journal of Rheumatology, vol. 25, no. 1, pp. 36–43, 1998. View at Google Scholar · View at Scopus
  33. A. Lima, M. Bernardes, H. Sousa et al., “SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients,” Pharmacogenomics, 2013. View at Google Scholar
  34. M. L. L. Prevoo, M. A. van 'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. M. N. Sadananda Adiga, S. Chandy, N. Ramachandra et al., “Methylenetetrahydrofolate reductase gene polymorphisms and risk of acute lymphoblastic leukemia in children,” Indian Journal of Cancer, vol. 47, no. 1, pp. 40–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Gibofsky, “Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis,” The American Journal of Managed Care, vol. 18, no. 13, supplement, pp. S295–S302, 2012. View at Google Scholar
  37. J. A. Rindfleisch and D. Muller, “Diagnosis and management of rheumatoid arthritis,” American Family Physician, vol. 72, no. 6, pp. 1037–1047, 2005. View at Google Scholar · View at Scopus
  38. P. Bohanec Grabar, D. Logar, B. Lestan, and V. Dolžan, “Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism,” European Journal of Clinical Pharmacology, vol. 64, no. 11, pp. 1057–1068, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 12, no. 2, article R71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Fenech, “The role of folic acid and Vitamin B12 in genomic stability of human cells,” Mutation Research. Fundamental and Molecular Mechanisms of Mutagenesis, vol. 475, no. 1-2, pp. 57–67, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Świerkot and J. Szechiński, “Methotrexate in rheumatoid arthritis,” Pharmacological Reports, vol. 58, no. 4, pp. 473–492, 2006. View at Google Scholar · View at Scopus
  42. T. Dervieux, D. Furst, D. O. Lein et al., “Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study,” Annals of the Rheumatic Diseases, vol. 64, no. 8, pp. 1180–1185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Dervieux, “Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability,” Rheumatology, vol. 48, no. 6, pp. 597–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. I. Vardavas, M. K. Linardakis, C. M. Hatzis, N. Malliaraki, W. H. Saris, and A. G. Kafatos, “Smoking status in relation to serum folate and dietary vitamin intake,” Tobacco Induced Diseases, vol. 4, article 8, 2008. View at Google Scholar
  45. H. E. Gabriel, J. W. Crott, H. Ghandour et al., “Chronic cigarette smoking is associated with diminished folate status, altered folate form distribution, and increased genetic damage in the buccal mucosa of healthy adults,” American Journal of Clinical Nutrition, vol. 83, no. 4, pp. 835–841, 2006. View at Google Scholar
  46. D. M. Mannino, J. Mulinare, E. S. Ford, and J. Schwartz, “Tobacco smoke exposure and decreased serum and red blood cell folate levels: data from the third National Health and Nutrition Examination Survey,” Nicotine and Tobacco Research, vol. 5, no. 3, pp. 357–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Nouri-Shirazi and E. Guinet, “Evidence for the immunosuppressive role of nicotine on human dendritic cell functions,” Immunology, vol. 109, no. 3, pp. 365–373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Kalra, S. P. Singh, J. C. Pena-Philippides, R. J. Langley, S. Razani-Boroujerdi, and M. L. Sopori, “Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model,” Clinical and Diagnostic Laboratory Immunology, vol. 11, no. 3, pp. 563–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Saevarsdottir, S. Wedrén, M. Seddighzadeh et al., “Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish Rheumatology Register cohorts,” Arthritis & Rheumatism, vol. 63, no. 1, pp. 26–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Vesperini, C. Lukas, B. Fautrel, X. le Loet, N. Rincheval, and B. Combe, “Tobacco exposure reduces radiographic progression in early rheumatoid arthritis. Results from the ESPOIR cohort,” Arthritis Care & Research, 2013. View at Google Scholar
  51. A. Finckh, S. Dehler, K. H. Costenbader, and C. Gabay, “Cigarette smoking and radiographic progression in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 8, pp. 1066–1071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Visser, Y. P. M. Goekoop-Ruiterman, J. K. De Vries-Bouwstra et al., “A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the Best study,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1333–1337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. M. L. Hetland, K. Stengaard-Pedersen, P. Junker et al., “Radiographic progression and remission rates in early rheumatoid arthritis—MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial,” Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1789–1795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Balsa, J. del Amo, F. Blanco et al., “Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms,” Rheumatology, vol. 49, no. 3, Article ID kep380, pp. 458–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Agrawal, R. Misra, and A. Aggarwal, “Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA,” Clinical Rheumatology, vol. 26, no. 2, pp. 201–204, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Saevarsdottir, H. Wallin, M. Seddighzadeh et al., “Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial,” Annals of the Rheumatic Diseases, vol. 70, no. 3, pp. 469–475, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. A. M. Wessels, S. M. van der Kooij, S. Le Cessie et al., “A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis,” Arthritis & Rheumatism, vol. 56, no. 6, pp. 1765–1775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Riazzoli, J. A. Nilsson, A. Teleman et al., “Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level,” Rheumatology, vol. 49, no. 11, pp. 2098–2103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Hoekstra, A. E. van Ede, C. J. Haagsma et al., “Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 5, pp. 423–426, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Tuková, J. Chládek, D. Němcová, J. Chládková, and P. Doležalová, “Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis,” Clinical and Experimental Rheumatology, vol. 27, no. 6, pp. 1047–1053, 2009. View at Google Scholar · View at Scopus